News of Note—Flu vaccines, CureVac and more

newspaper
In this week's news of note, InvVax reported positive preclinical results for a universal flu vaccine candidate. (Pixabay)

Here is some other vaccine news of note for the week:

> About 37% of U.S. adults got a flu vaccine last year, according to the CDC. The figure represented about a 6% decline from the prior year. MarketWatch article

> CureVac started a phase 1 study of a mRNA-based rabies vaccine candidate. Release

> ImmusanT kicked off a phase 2 study of its Nexvax2 in patients with celiac disease. Release

> A report found that low vaccine confidence in Europe is contributing to a higher number of disease outbreaks. Reuters article

> Privately held biotech InvVax touted preclinical results for its universal flu vaccine candidate. Release

Suggested Articles

The scientific community has again been caught off guard and industry officials are talking about implementing better preventive measures.

Sanofi didn't hesitate to enter Zika vaccine R&D, and despite the associated scandal, the company is again jumping into emerging disease vaccine R…

NIH and Moderna will need a coronavirus vaccine manufacturer, and and no major pharmaceutical company has stepped up.